Inhibition of Arg-1 and iNOS expression inhibits polyamine production and the TCA cycle, thereby further suppressing the immunosuppressive capacity of PMN-MDSCs and enhancing the antitumor effects of anti-PD1 mAb therapy in B16-F10 and 4 T1 mouse tumor models [36]. The gene discussed is ARG1; the disease is neoplasm.